# Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.

> **NCT04500860** · PHASE1 · COMPLETED · sponsor: **Kasr El Aini Hospital** · enrollment: 90 (actual)

## Conditions studied

- Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence

## Interventions

- **DRUG:** Low dose tadalafil 5 mg
- **DRUG:** Tolterodine 4 Mg Oral Capsule, Extended Release
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04500860
- **Lead sponsor:** Kasr El Aini Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2022-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04500860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04500860, "Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04500860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*